Ind-Swift Laboratories Q2 Results 2026: PAT ₹34 Cr (+325% YoY)
Q2 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹240Cr
- +50.9% YoY
- +25.7% QoQ
- Net profit
- ₹34Cr
- +325% YoY
- +36% QoQ
- Margin
- 19%
- +14.3 pp YoY
- +2 pp QoQ
Guidance rank: #1 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q2 FY27 call signalled
4 of 4 strong
The short version
FY27: Ind-Swift reiterates guidance of over 50% revenue growth, with H1 FY27 revenue at ₹421 crore (up 35.79% YoY) and confident of meeting full-year targets. Ind-Swift Laboratories expects over 50% revenue growth in FY27, with comfortable achievement of guidance based on H1 performance.
From Ind-Swift Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 10 Nov 2026.
How did Ind-Swift Laboratories' revenue grow in the September 2026 quarter?
- FY27: Ind-Swift reiterates guidance of over 50% revenue growth, with H1 FY27 revenue at ₹421 crore (up 35.79% YoY) and confident of meeting full-year targets.
- FY28-29: Growth driven by ramp-up of existing pipeline and approved molecules; new R&D molecules expected to start registrations in early FY28 and commercialization by late FY28/FY29.
- FY28: CDMO revenues (currently ₹65 crore in H1 FY27) anticipated to grow with increased run-rate; contract manufacturing to comprise ~35% of export revenues, own brands ~65%.
- FY30: Target to cross ₹1,500 crore revenues with 20-25% CAGR over medium term and 200-300 bps EBITDA margin expansion.
2 more points from Ind-Swift Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Ind-Swift Laboratories' margins in Q2 FY27?
See what Ind-Swift Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Ind-Swift Laboratories planning?
- Ongoing ₹250 crore growth capex covering:
- Samba facility EU-GMP and PIC/S upgrade (₹45 crore)
- Derabassi warehouse development adjacent to 100% EOU facility
- New R&D infrastructure development
- Capacity debottlenecking at manufacturing sites
- Construction started on Derabassi warehouse, expected completion in 10-12 months
- Samba facility upgrades aimed at unlocking regulated market access for topical and oral formulations, with ANVISA visit expected last quarter and PIC/S approval anticipated next year
2 more points from Ind-Swift Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Ind-Swift Laboratories raising money or cutting debt?
See what Ind-Swift Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Ind-Swift Laboratories' order book?
- Orders are currently in hand as per Gagan Aggarwal's statement in Q2 FY27 call (Page 14).
- Raw materials are lined up, and manufacturing facilities are equipped, indicating preparedness to fulfill orders.
- Ongoing discussions with two other customers beyond Viatris and Aerotex are in advanced stages, with hopes to conclude deals in the last quarter (Page 12).
2 more points from Ind-Swift Laboratories Ltd's call on order book
Create a free account to keep reading this call
Ind-Swift Laboratories Ltd — Quarterly revenue & net profit
Ind-Swift Laboratories Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 240 | 159 | +50.9% | 191 | +25.7% |
| Operating profit (EBITDA) | 45 | 7 | +542.9% | 33 | +36.4% |
| Operating margin | 19% | 4.7% | +14.3 pp | 17% | +2 pp |
| Profit before tax | 43 | 10 | +330% | 33 | +30.3% |
| Net profit (PAT) | 34 | 8 | +325% | 25 | +36% |
| EPS (₹) | 3.94 | 0.98 | +302% | 2.84 | +38.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹34 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Ind-Swift Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- 1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ind-Swift Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ind-Swift Laboratories Ltd Q2 FY27 results?
Ind-Swift Laboratories reported net profit of ₹34 Cr (+325% YoY) on revenue of ₹240 Cr (+50.9% YoY) in Q2 FY27.
What is Ind-Swift Laboratories Ltd share price analysis?
Ind-Swift Laboratories Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 33.1 with a market cap of ₹3,041 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ind-Swift Laboratories Ltd planning capital expenditure?
Ongoing ₹250 crore growth capex covering:.
Keep Ind-Swift Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
